Literature DB >> 17764491

Poor diagnostic accuracy of a single fasting plasma citrulline concentration to assess intestinal energy absorption capacity.

Job H C Peters1, Nicolette J Wierdsma, Tom Teerlink, Paul A M van Leeuwen, Chris J J Mulder, Ad A van Bodegraven.   

Abstract

OBJECTIVES: Our aim was to explore the diagnostic value of fasting citrulline concentrations to detect decreased intestinal energy absorption in patients with recently diagnosed celiac disease (CeD), refractory celiac disease (RCeD), and short bowel syndrome (SBS). Decreased intestinal energy absorption is regarded a marker of intestinal failure.
METHODS: Fasting plasma citrulline concentrations were determined by high performance liquid chromatography (HPLC) in a prospective study of 30 consecutive adult patients (15 CeD, 9 RCeD, and 16 SBS) and 21 healthy subjects. Intestinal energy absorption capacity using bomb calorimetry was determined in all patients and healthy subjects and was regarded as the gold standard for intestinal energy absorption function.
RESULTS: The mean fasting plasma citrulline concentration was lower in RCeD patients than in healthy subjects (28.5+/-9.9 vs 38.1+/-8.0 micromol/L, P<0.05) and CeD patients (28.5+/-9.9 vs 38.1+/-6.4 micromol/L, P<0.05), however, clearly within reference values. The mean intestinal energy absorption capacity was lower in SBS patients than in healthy subjects (64.3+/-18.2 vs 90.3+/-3.5%, P<0.001), CeD patients (64.3+/-18.2 vs 89.2+/-3.4%, P<0.001), and the RCeD group (64.3+/-18.2 vs 82.3+/-11.7%, P<0.01). No relation was observed between fasting plasma citrulline concentration and intestinal energy absorption capacity (Pearson r=0.09, P=0.56). The area under the ROC curve for fasting plasma citrulline to detect decreased intestinal energy absorption capacity (i.e., <85%) was 0.50.
CONCLUSION: Fasting plasma citrulline concentrations have poor test characteristics for detection of decreased intestinal energy absorption capacity in patients with enterocyte damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17764491     DOI: 10.1111/j.1572-0241.2007.01513.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

Review 1.  Serum markers in the clinical management of celiac disease.

Authors:  Marlou Adriaanse; Daniel A Leffler
Journal:  Dig Dis       Date:  2015-04-22       Impact factor: 2.404

2.  Plasma citrulline kinetics and prognostic value in critically ill patients.

Authors:  Gaël Piton; Cyril Manzon; Elisabeth Monnet; Benoit Cypriani; Olivier Barbot; Jean-Christophe Navellou; Franck Carbonnel; Gilles Capellier
Journal:  Intensive Care Med       Date:  2010-04       Impact factor: 17.440

3.  Citrulline Generation Test: What Does It Measure?

Authors:  Mahmoud A Mohammad; Inka C Didelija; Barbara Stoll; Juan C Marini
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-10-24       Impact factor: 4.016

4.  Is serum citrulline measurement clinically useful in coeliac disease?

Authors:  Emanuela Miceli; Nicoletta Poggi; Antonio Missanelli; Paola Bianchi; Remigio Moratti; Gino Roberto Corazza
Journal:  Intern Emerg Med       Date:  2008-04-25       Impact factor: 3.397

Review 5.  Diagnosing small bowel malabsorption: a review.

Authors:  Cinzia Papadia; Antonio Di Sabatino; Gino Roberto Corazza; Alastair Forbes
Journal:  Intern Emerg Med       Date:  2012-11-21       Impact factor: 3.397

6.  Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome.

Authors:  Palle Bekker Jeppesen
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

7.  Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia.

Authors:  Désirée van Noord; Peter B F Mensink; Robert J de Knegt; Martine Ouwendijk; Jan Francke; Anneke J van Vuuren; Bettina E Hansen; Ernst J Kuipers
Journal:  Dig Dis Sci       Date:  2010-07-15       Impact factor: 3.199

8.  Diagnosing malabsorption in the intensive care unit.

Authors:  Martijn B Keur; Albertus Beishuizen; Adriaan A van Bodegraven
Journal:  F1000 Med Rep       Date:  2010-01-27

9.  Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.

Authors:  Douglas L Seidner; Francisca Joly; Nader N Youssef
Journal:  Clin Transl Gastroenterol       Date:  2015-06-25       Impact factor: 4.488

Review 10.  Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis.

Authors:  Konstantinos C Fragkos; Alastair Forbes
Journal:  United European Gastroenterol J       Date:  2017-10-12       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.